INT308559

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 4
Disease Relevance 1.72
Pain Relevance 0.37

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (VPS45) vesicle-mediated transport (VPS45) Golgi apparatus (VPS45)
intracellular (VPS45) molecular_function (VPS45) cellular_component (VPS45)
VPS45 (Homo sapiens)
Pain Link Frequency Relevance Heat
alcohol 4 98.16 Very High Very High Very High
antagonist 12 97.28 Very High Very High Very High
Calcium channel 8 93.60 High High
beta blocker 4 91.32 High High
cINOD 8 89.60 High High
COX2 4 85.76 High High
iatrogenic 4 46.00 Quite Low
Pain 12 5.00 Very Low Very Low Very Low
cva 12 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hypertension 272 99.64 Very High Very High Very High
Cancer 112 90.00 High High
INFLAMMATION 8 88.16 High High
Cardiovascular Disease 32 5.00 Very Low Very Low Very Low
Renal Cancer 12 5.00 Very Low Very Low Very Low
Pain 12 5.00 Very Low Very Low Very Low
Myocardial Infarction 12 5.00 Very Low Very Low Very Low
Heart Rate Under Development 8 5.00 Very Low Very Low Very Low
Death 8 5.00 Very Low Very Low Very Low
Chronic Renal Failure 8 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Each of these classes of antihypertensive agents has successfully controlled VSP inhibitor–induced hypertension on an individual patient basis.
Regulation (controlled) of VSP inhibitor associated with hypertension
1) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2864290 Disease Relevance 0.54 Pain Relevance 0.19
Because BP elevation is a reversible mechanism-based effect of VSP inhibition, discontinuation or where appropriate, dose reduction of the VSP inhibitor can also be used to control VSP inhibitor–induced hypertension.
Regulation (control) of VSP inhibitor associated with hypertension
2) Confidence 0.38 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2864290 Disease Relevance 0.45 Pain Relevance 0
To achieve the BP control goals, physicians should be mindful of other agents that could magnify the BP-elevating effects of the VSP inhibitors.
Regulation (effects) of VSP
3) Confidence 0.38 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2864290 Disease Relevance 0.34 Pain Relevance 0.18
Because BP elevation is a reversible mechanism-based effect of VSP inhibition, discontinuation or where appropriate, dose reduction of the VSP inhibitor can also be used to control VSP inhibitor–induced hypertension.
Regulation (effect) of VSP associated with hypertension
4) Confidence 0.38 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2864290 Disease Relevance 0.39 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox